Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, “Lind”). Under the terms of the Agreement, an initial CAD$3.5 million will be funded pursuant to the issuance of a convertible security (a “Convertible Security”) which is expected to occur on or around May 12, 2021 (“First Tranche”). The Agreement also contemplates the issuance of a second Convertible Security upon the mutual agreement of the Company and Lind for gross proceeds to the Company of up to CAD$6.5 million (the “Second Tranche”).